Gilead dish­es out $66M for San Diego biotech's 'ten­ta­cles' in can­cer, in­flam­ma­tion

Gilead will pony up $66 mil­lion in an up­front pay­ment and eq­ui­ty in­vest­ment to col­lab­o­rate with Ten­tar­ix Bio­ther­a­peu­tics on bi­o­log­ics for in­flam­ma­to­ry dis­eases and on­col­o­gy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER